Bris­tol My­ers push­es back ‘peak’ for new prod­uct sales, cit­ing chal­leng­ing up­take for So­tyk­tu, Camzyos

Bris­tol My­ers Squibb is fac­ing sev­er­al ques­tions about its mid-term fu­ture af­ter it de­layed sales pro­jec­tions for its new prod­uct port­fo­lio, which in­cludes Re­blozyl and Abec­ma.

The Big Phar­ma com­pa­ny said Thurs­day in its third-quar­ter fi­nan­cial re­sults that it now ex­pects to achieve “at least $10 bil­lion” in sales from these drugs in 2026. Bris­tol My­ers pre­vi­ous­ly fore­cast $10 bil­lion to $13 bil­lion in sales of these ther­a­pies in 2025. The de­lay comes as CEO Gio­van­ni Caforio pre­pares to step down and hand the reins to cur­rent COO Chris Boern­er on Nov. 1.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER